Segment Information (Tables)

3 Months Ended

Mar. 31, 2025

Segment Information.

Schedule of reconciliation of collaboration revenue to net loss for segment

	Three months ended March 31, 2025		Three months ended March 31, 2024
Collaboration revenue	$	6,473	$	19,516
External research and development (1):
Anti-tau antibody program (VY7523)		4,249		2,946
SOD1 silencing gene therapy program (VY9323)		1,886		1,964
Tau silencing gene therapy program (VY1706)		3,174		996
Partnered programs (2)		991		2,040
Other programs and platforms (3)		3,181		2,760
Internal research and development (4)		9,958		9,480
Facilities and other research and development (5)		8,087		6,906
General and administrative, total		9,640		8,607
Interest income		3,291		4,867
Other income		418		-
Income tax provision		37		14
Net loss	$	(31,021)	$	(11,330)

1) External research and development is allocated to the Company’s programs and platforms and includes contract development and manufacturing organization expenses, laboratory supplies, the costs of non-employee consultants and contractors, and all other expenses paid to external vendors.

2) Partnered programs include programs in which the Company is collaborating with partners to develop AAV gene therapy products and product candidates under the Company’s 2019 and 2023 Neurocrine Collaboration Agreements, and the License and Collaboration Agreement the Company entered into with Novartis on December 28, 2023.

3) Other programs and platforms consist of expenses related to other early research programs and platforms which are not considered quantitatively and qualitatively significant, including capsid discovery, non-viral delivery, and early research programs.

4) Internal research and development consists of employee-related expenses including salaries, benefits, and stock-based compensation expense.

5) Depreciation and amortization are included within facilities and other research and development, which are the same as the amounts in the accompanying condensed consolidated statements of operations as the Company operates as a single operating segment.